Biotech RadarJobs updated

COMPANY

Scholar Rock, Inc.

HQ: Cambridge, MA source · scholarrock.com ↗ · New England

FDA-approved therapeutic company Clinical Phase 3

35 open jobs · last seen Oct 23, 2026 · 9 sources

Location: Cambridge, MA · source · Oct 14, 2026

Profile checked Oct 10, 2026

Keywords: Spinal Muscular Atrophy SMA Spinal Muscular Atrophy Type 2 Spinal Muscular Atrophy Type 3 Neuromuscular Manifestations Anti-myostatin Neuromuscular Diseases Muscular Atrophy Atrophy Facioscapulohumeral Muscular Dystrophy Overweight and Obesity Apitegromab SRK-439 SRK-181 SRK-015

35Open jobs9Trials (company is sponsor)1FDA records (2 yrs)

Hiring

TitleLocation (from posting)Employer postedFirst seen
Senior Director, Patient Advocacy & Communications Lead, EMEAZugOct 20, 2026Oct 21, 2026
Director, External & CMC Quality AssuranceCambridge, MAOct 8, 2026Oct 11, 2026
Director, International Indirect TaxDublinOct 8, 2026Oct 11, 2026
Director, Domestic TaxCambridge, MAOct 8, 2026Oct 11, 2026
Senior Manager/Associate Director, Accounting EMEADublinOct 7, 2026Oct 11, 2026

See all 35 jobs

Trial and FDA signals

Job counts as of Oct 18, 2026. All trial and FDA signals

Timeline

  1. FDA FDA New drug/biologic (novel): ISEMBYLD (apitegromab-mstn) — BLA761463, Sep 11, 2026. Applicant at approval: Scholar Rock, Inc. source ↗
  2. Trial start 2: Phase 2 Study Evaluating Apitegromab for the Treatment of FSHD source ↗
  3. Trial start Phase 1: A Single- and Multiple-Ascending Dose Study of SRK-439 in Healthy Adults source ↗
  4. Trial start Phase 2: A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy source ↗
  5. Trial start Phase 2: Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese source ↗
  6. Trial start Phase 3: Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab source ↗
  7. Trial start Phase 3: Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam source ↗
  8. Trial start Phase 1: SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON) source ↗
  9. Trial start Phase 2: An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 9

RecordTitlePhaseStatusStartPrimary completion
NCT07047144A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular AtrophyPhase 2RecruitingSep 15, 20252028-11 (estimated)
NCT07435129Phase 2 Study Evaluating Apitegromab for the Treatment of FSHD2RecruitingJul 30, 20262028-06 (estimated)
NCT05626855Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of ApitegromabPhase 3Active, not recruitingApr 17, 2023Nov 1, 2026 (estimated)
NCT06877689EAP of Apitegromab for Patients With Spinal Muscular AtrophyNot listedNo longer availableNot listedNot listed
NCT07444294A Single- and Multiple-Ascending Dose Study of SRK-439 in Healthy AdultsPhase 1RecruitingNov 21, 2025Dec 17, 2026 (estimated)
NCT06445075Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or ObesePhase 2CompletedMay 21, 2024Mar 4, 2025 (actual)
NCT05156320Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or RisdiplamPhase 3CompletedApr 14, 2022Dec 18, 2024 (actual)
NCT04291079SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON)Phase 1CompletedApr 23, 2020Apr 14, 2025 (actual)
NCT03921528An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular AtrophyPhase 2CompletedApr 22, 2019Jan 19, 2021 (actual)

FDA records (last 2 years)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Open jobs 35

TitleLocation (from posting, not HQ)Employer postedFirst seenLevel
Senior Director, Patient Advocacy & Communications Lead, EMEAZugOct 20, 2026Oct 21, 2026Not stated
Director, External & CMC Quality AssuranceCambridge, MAOct 8, 2026Oct 11, 2026Senior
Director, International Indirect TaxDublinOct 8, 2026Oct 11, 2026Senior
Director, Domestic TaxCambridge, MAOct 8, 2026Oct 11, 2026Senior
Senior Manager/Associate Director, Accounting EMEADublinOct 7, 2026Oct 11, 2026Senior
Associate Director/ Director FP&A EMEAZugOct 7, 2026Oct 11, 2026Senior
Office Manager and Executive Administrative CoordinatorMiami, FLOct 5, 2026Oct 11, 2026Mid
Sr. Scientist, Antibody EngineeringCambridge, MAOct 5, 2026Oct 11, 2026Senior
Associate Director, IT Service Delivery & SupportCambridge, MAOct 5, 2026Oct 11, 2026Senior
Sr. Director, Infrastructure & OperationsCambridge, MAOct 5, 2026Oct 11, 2026Senior
Sr. Director, Enterprise Business ApplicationsCambridge, MAOct 5, 2026Oct 11, 2026Senior
Workplace Services Senior ManagerCambridge, MASep 30, 2026Oct 11, 2026Senior
Senior Manager, Lab OperationsCambridge, MASep 30, 2026Oct 11, 2026Senior
Director, Market InsightsCambridge, MASep 29, 2026Oct 11, 2026Senior
Payroll ManagerCambridge, MASep 28, 2026Oct 11, 2026Mid
Principal Scientist, Bioanalytical SpecialistCambridge, MASep 28, 2026Oct 11, 2026Senior
Principal Scientist, Biomarker DevelopmentCambridge, MASep 25, 2026Oct 11, 2026Senior
Associate Director/Senior Clinical Trial ManagerCambridge, MASep 23, 2026Oct 11, 2026Senior
Medical Director/Sr Director, Clinical ResearchCambridge, MASep 22, 2026Oct 11, 2026Senior
Senior Manager /Associate Director, BiostatisticsCambridge, MASep 22, 2026Oct 11, 2026Senior
Senior Director, Device EngineeringCambridge, MASep 18, 2026Oct 11, 2026Senior
Director, Pricing & Contracting OperationsCambridge, MASep 17, 2026Oct 11, 2026Senior
Associate Director, Regulatory StrategyCambridge, MASep 10, 2026Oct 11, 2026Senior
Associate Director/Director, Medical OperationsCambridge, MASep 2, 2026Oct 11, 2026Senior
Director, Global Quality ControlCambridge, MASep 1, 2026Oct 11, 2026Senior
Senior Engineer, Downstream Manufacturing Science & Technology (MSAT)Cambridge, MAAug 31, 2026Oct 11, 2026Senior
Senior Manager, ContractsCambridge, MAAug 25, 2026Oct 11, 2026Senior
Senior AccountantCambridge, MAAug 18, 2026Oct 11, 2026Senior
Senior Manager / Associate Director, HCP Marketing (US)Cambridge, MAAug 10, 2026Oct 11, 2026Senior
Director/Sr. Director, Clinical PharmacologyCambridge, MAAug 4, 2026Oct 11, 2026Senior
Associate Director/Director, Patient Marketing (US)Cambridge, MAJul 28, 2026Oct 11, 2026Senior
Associate Director/Director, Clinical Operations ComplianceCambridge, MAJul 7, 2026Oct 11, 2026Senior
Sr. Director, HR Business Partner (R & D and Tech Ops & Quality)Cambridge, MAJun 8, 2026Oct 11, 2026Senior
Vice President, Head of Regulatory StrategyCambridge, MAMar 16, 2026Oct 11, 2026Executive
Sr. Medical Director, Drug Safety & PharmacovigilanceCambridge, MAJul 16, 2025Oct 11, 2026Senior

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Connect

See your connections at Scholar Rock on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-12

Feedback